Immunohematogical markers in Graves disease

Not Applicable

• Conditions: Health Condition 1: E050- Thyrotoxicosis with diffuse goiter

• Registration Number: CTRI/2021/12/038899
• Lead Sponsor: Jayanthy Ramesh

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Any new patient with thyrotoxicosis

Exclusion Criteria

Those who refuse consent

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
o of Patients diagnosed with graves vs toxic nodules vs toxic MNG vs hashimotos thyroiditisTimepoint: No of Patients diagnosed with graves vs toxic nodules vs toxic MNG vs hashimotos thyroiditis

Secondary Outcome Measures

Name	Time	Method
Follow up of Graves� disease patientsTimepoint: 6 months